Clinical trial
A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell Lymphomas
NCT05574114 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell Lymphomas
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 5, 2022
- Completion date
- October 31, 2026
- Enrollment
- 20 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin lymphoma, non-hodgkin's lymphoma refractory, non-hodgkin's lymphoma, relapsed